AKT1 and malignant colon neoplasm: The combination treatment reduced GPR30 and p-Akt levels in MC38 and CT26 colon cancer tissues with an obvious decrease in estradiol production compared to the anti-PD-1 monotherapy (Fig. 10E and F).